A higher LAG-3 expression has been associated with longer progression-free survival in patients with melanoma in the RELATIVITY-047 trial independent of the treatment arm (anti-PD-1 or combination anti-PD-1 and anti-LAG-3)6. Here, LAG3 is linked to melanoma.